# Self-driving laboratories that run the cancer biology hypothesis loop autonomously

Source: https://onco.cc/ideas/idea-moon-self-driving-cancer-labs/  
OnCo record `idea-moon-self-driving-cancer-labs` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Robotic labs guided by AI that design experiments on tumour models, run them, read the results and design the next ones, around the clock, with every result published openly.

## Summary

Autonomous laboratories exist in chemistry and materials science, and cloud labs and robotic organoid culture are emerging in biology. Cancer biology is limited by slow, poorly reproducible manual experimentation. The proposal is a network of self-driving cancer labs: automated organoid and cell line culture, perturbation, imaging and sequencing readouts, active-learning experiment selection against defined questions (resistance mechanisms, combination synergy, dependency mapping), and automatic public deposition of raw data and protocols.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Self-driving labs produce reproducible, reusable results at ten times the throughput and a fraction of the cost per experiment of conventional labs, and their findings translate at a higher rate.
- Rationale: Automation removes the variability that undermines reproducibility and lets exploration scale with compute rather than with postdoc hours; open deposition keeps the results usable.
- Proposed test: Build one facility focused on resistance to KRAS inhibitors; compare throughput, replication rates and independent validation of findings against a conventional consortium over three years.
- Maturity: preclinical-evidence
- Actor: engineering

## Sources

- Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019): https://doi.org/10.1093/biostatistics/kxx069

## Connected records

- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/), [CRISPR functional genomics](https://onco.cc/technologies/crispr-screens/), [Patient-derived organoids](https://onco.cc/technologies/organoids/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- companies: [Recursion Pharmaceuticals](https://onco.cc/companies/recursion/)
- bottlenecks: [Lab models that fail to predict what happens in patients](https://onco.cc/bottlenecks/b-preclinical-models/), [Preclinical results do not reproduce](https://onco.cc/bottlenecks/b-reproducibility/), [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)
- key papers: [Estimation of clinical trial success rates and related parameters](https://onco.cc/key-papers/paper-wong-biostatistics/)

---
JSON: https://onco.cc/api/v1/entities/idea-moon-self-driving-cancer-labs.json